Dihexa and the VA’s GLP-1 Alcohol Trial: A Nootropic Adjunct for Cognitive Deficits in Veterans?
Long-term safety data for many peptides discussed here is limited. Risk profiles should be interpreted accordingly.
What Is Dihexa?
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small peptide. It was developed from angiotensin IV. Angiotensin IV is a fragment of a larger protein that helps control blood pressure. Dihexa is not a natural substance. It is a synthetic molecule made in a laboratory.
Dihexa is often called a nootropic. A nootropic is a compound that might improve mental functions. These functions include memory or focus. Dihexa stands out because it may help the brain repair itself. It does this by binding to a specific receptor. That receptor is called hepatocyte growth factor receptor. It is also known as c-Met.
Hepatocyte growth factor (HGF) is a protein that helps cells grow and survive. The c-Met receptor is like a lock. HGF is the key. When HGF turns the lock it tells cells to grow and connect. Dihexa acts like a spare key for that same lock. It can activate c-Met even without HGF. This activation may lead to new connections between brain cells. These connections are called synapses. More synapses can mean better thinking and memory.
How Dihexa Works in the Brain
Dihexa's mechanism centers on the c-Met receptor. This receptor sits on the surface of many cell types. In the brain it is found on neurons. Neurons are the cells that send electrical signals. When Dihexa binds to c-Met it triggers a chain of events inside the neuron. This chain is called a signaling cascade. The cascade promotes synaptic plasticity. Synaptic plasticity is the brain's ability to strengthen or weaken connections over time.
Published research shows that Dihexa can cross the blood-brain barrier. The blood-brain barrier is a tight wall of cells that protects the brain. Many drugs cannot pass this wall. Dihexa passes it very well. A 2012 study found that Dihexa reaches the brain in high amounts. Once there it stimulates the growth of new dendritic spines. Dendritic spines are tiny bumps on neurons. They receive signals from other neurons. More spines can mean faster and clearer communication.
Dihexa also increases the supply of brain-derived neurotrophic factor (BDNF). BDNF is a protein that supports neuron survival. It helps new neurons grow. It also protects old neurons from damage. Higher BDNF levels are linked to better learning. They are also linked to resistance against brain diseases. The literature on Dihexa suggests it may reverse cognitive deficits. These deficits can come from injury or disease.
What Is the VA's GLP-1 Alcohol Trial?
The U.S. Department of Veterans Affairs (VA) is running a clinical trial. This trial tests a GLP-1 receptor agonist for alcohol use disorder. GLP-1 stands for glucagon-like peptide-1. It is a hormone that controls blood sugar and appetite. A receptor agonist is a substance that activates a receptor. Semaglutide is one GLP-1 agonist. It is sold as Ozempic or Wegovy. The VA trial is exploring if semaglutide can reduce alcohol cravings.
Veterans have high rates of alcohol use disorder. This disorder harms the brain over time. It can cause cognitive deficits. Cognitive deficits are problems with memory attention or decision-making. The VA trial aims to help veterans stop drinking. But stopping drinking does not always fix the brain damage. Some deficits may remain. This is where a nootropic like Dihexa might be considered. It is not part of the trial. It is a theoretical adjunct. An adjunct is something added to help the main treatment.
The VA trial is a randomized controlled trial. That means participants are assigned by chance to get the drug or a placebo. A placebo is a fake treatment with no active ingredient. The trial will measure drinking outcomes. It will also measure changes in brain function. The results are not yet published. The trial is still ongoing as of 2025.
Why Cognitive Deficits Matter in Alcohol Use Disorder
Alcohol damages the brain in several ways. It kills neurons directly. It causes inflammation. Inflammation is the body's response to injury. Chronic inflammation can harm healthy tissue. Alcohol also reduces BDNF levels. Low BDNF makes it harder for the brain to repair itself. This damage shows up as cognitive deficits. Veterans with alcohol use disorder often struggle with memory. They may have trouble planning or controlling impulses.
These deficits make recovery harder. A person with poor impulse control may relapse. A person with memory problems may forget coping strategies. Standard treatments for alcohol use disorder focus on stopping drinking. They do not directly target brain repair. A nootropic adjunct could fill this gap. It might help the brain heal faster. It might restore lost cognitive functions. This could improve long-term recovery outcomes.
Published research on alcohol-related brain damage points to synaptic loss. Synapses are the connections between neurons. Alcohol use disorder reduces synapse density. This loss is linked to cognitive decline. A compound that rebuilds synapses could be useful. Dihexa's ability to increase dendritic spines makes it a candidate. But no human trials have tested this yet.
Dihexa as a Theoretical Adjunct: The Research Picture
Dihexa has been studied mainly in animals. A 2012 study used rats with brain damage. The rats were given a drug called scopolamine. Scopolamine blocks memory formation. It mimics some aspects of dementia. Dihexa reversed the memory problems. The treated rats performed better on maze tests. Their brains showed new synapse growth.
Another study from 2014 looked at Dihexa in a model of Parkinson's disease. Parkinson's is a brain disorder that affects movement. It also causes cognitive decline. Dihexa improved motor function in the animals. It also protected dopamine neurons. Dopamine is a chemical messenger important for motivation and reward. Alcohol use disorder disrupts dopamine pathways. This disruption contributes to cravings and cognitive fog.
No human trials of Dihexa exist. Its safety profile is unknown. The animal data is promising but limited. Dihexa is not approved by the FDA. It is sold as a research chemical. This means it is not meant for human use. The VA trial does not include Dihexa. Any discussion of combining Dihexa with a GLP-1 agonist is speculative. It is based on mechanistic reasoning. Mechanistic reasoning means guessing from how things work in theory.
Semax: Another Nootropic with Possible Relevance
Semax (a synthetic peptide derived from ACTH) is another nootropic. ACTH is a hormone involved in stress response. Semax was developed in Russia. It is used there for stroke recovery and cognitive disorders. Semax also increases BDNF. It raises levels of nerve growth factor (NGF). NGF is another protein that supports neuron health. Semax is given as a nasal spray. This allows it to bypass the blood-brain barrier quickly.
Published research on Semax shows it can improve attention and memory. A 2018 review of Russian studies found benefits in patients with brain injuries. Semax reduced cognitive fatigue. It also improved processing speed. Processing speed is how fast the brain handles information. Alcohol use disorder slows processing speed. Semax might help correct this. But like Dihexa Semax lacks large Western clinical trials.
Semax has a different mechanism than Dihexa. It works through melanocortin receptors. These receptors are involved in inflammation and neuroprotection. Combining Semax with Dihexa could theoretically target multiple pathways. One pathway is synaptic growth via c-Met. The other is neuroprotection via melanocortin receptors. This combination has not been studied. It is purely hypothetical.
Other Peptides in the Nootropic Conversation
Several other peptides are often discussed alongside Dihexa. Cerebrolysin (a mixture of peptides derived from pig brain) is one. It is used in some countries for dementia and stroke. Cerebrolysin contains many neurotrophic factors. These factors mimic the brain's own repair signals. A 2019 meta-analysis found Cerebrolysin improved cognitive outcomes after stroke. It might also help in alcohol-related brain damage. But it requires intravenous infusion. This makes it less practical than a pill or nasal spray.
MOTS-c (a mitochondrial-derived peptide) is another compound. Mitochondria are the power plants of cells. MOTS-c helps mitochondria work better. It improves energy metabolism. The brain uses a lot of energy. Alcohol disrupts energy production in neurons. MOTS-c could restore this. A 2021 study in mice showed MOTS-c improved cognitive function during aging. It also reduced inflammation. These effects could complement Dihexa's synaptic repair.
Pinealon (a short peptide of three amino acids) is also mentioned. Amino acids are the building blocks of proteins. Pinealon is thought to protect DNA from damage. It may also regulate gene expression. Gene expression is how cells read DNA instructions. Alcohol can alter gene expression in the brain. Pinealon might normalize this. The research on Pinealon is very limited. Most studies come from Russia. They are not well replicated.
Selank (a synthetic peptide related to tuftsin) is an anti-anxiety nootropic. Tuftsin is a natural immune system peptide. Selank increases BDNF. It also balances immune signals in the brain. Anxiety is common in alcohol withdrawal. Selank could ease this symptom. It might also support cognitive recovery. But its effects are milder than Dihexa's. Selank is often used alongside Semax in Russian practice.
Practical Considerations and Open Questions
Dihexa is not available as a medication. It is sold by some vendors for research purposes. Purity and quality are unregulated. The long-term effects are unknown. Animal studies used very low doses. The human equivalent dose is unclear. Dihexa is extremely potent. It binds c-Met with high affinity. This means a tiny amount has a big effect. Overdosing could cause uncontrolled cell growth. This is a theoretical cancer risk. No carcinogenicity studies have been done.
The VA trial focuses on semaglutide alone. Adding a nootropic would require a new trial. That trial would need to test safety first. It would need to measure cognitive outcomes. Standard cognitive tests include memory recall and reaction time. Brain imaging could show synapse density changes. Such a trial is years away. The current evidence does not support using Dihexa in humans.
Open questions remain. Does Dihexa work the same in a human brain as in a rat brain? Can it reverse years of alcohol damage? Would it interact with semaglutide? Semaglutide affects appetite and reward pathways. Dihexa affects synaptic growth. The combination might be safe. Or it might overstimulate certain brain circuits. Only controlled research can answer this.
The concept of a nootropic adjunct is appealing. Veterans deserve treatments that address the full scope of their injuries. Cognitive deficits are a hidden wound. They make everyday life harder. They reduce quality of life. A compound that rebuilds the brain could change recovery. But Dihexa is not that compound yet. It is a research lead. It is a molecule with potential. It is not a proven therapy.
Other peptides like Semax for post-COVID brain fog have more human data. Semax has been used in clinical settings for decades. Its safety record is better documented. Still it is not approved in the U.S. The regulatory path for peptides is slow. The FDA panel's recent endorsement of peptide therapeutics may speed things up. But Dihexa is far from that stage.
For now the VA trial proceeds without Dihexa. The results will inform future research. If semaglutide helps veterans stop drinking the next question is how to repair their brains. Dihexa and similar compounds may enter that conversation. The science is young. The need is great. Caution is necessary.